TY  - JOUR
AU  - Gonzalez Del Alba, A
AU  - Mendez-Vidal, M J
AU  - Vazquez, S
AU  - Castro, E
AU  - Climent, M A
AU  - Gallardo, E
AU  - Gonzalez-Billalabeitia, E
AU  - Lorente, D
AU  - Maroto, J P
AU  - Arranz, J A
PY  - 2021
DO  - 10.1007/s12094-021-02561-5
UR  - http://hdl.handle.net/10668/17228
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced...
LA  - en
KW  - Androgen
KW  - Biomarkers
KW  - Castration
KW  - Molecular
KW  - Research
KW  - Androgen antagonists
KW  - Androstenes
KW  - Antineoplastic agents
KW  - Benzamides
KW  - Combined modality therapy
KW  - Docetaxel
KW  - Genes, BRCA1
KW  - Genes, BRCA2
KW  - Genetic testing
KW  - Humans
KW  - Male
KW  - Medical oncology
KW  - Nitriles
KW  - Orchiectomy
KW  - Phenylthiohydantoin
KW  - Phthalazines
KW  - Piperazines
KW  - Prostatic neoplasms
KW  - Prostatic neoplasms, castration-resistant
KW  - Radiotherapy
KW  - Randomized controlled trials as topic
KW  - Societies, medical
KW  - Spain
KW  - Thiohydantoins
TI  - SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
TY  - research article
VL  - 23
ER  -